Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06989853 · ClinicalTrials.gov registry record · Early Phase 1
Methamphetamine and Troriluzole
A Early Phase 1 study of Methamphetamine Use Disorder, sponsored by William Stoops.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06989853: Recruiting Early Phase 1 study of Methamphetamine Use Disorder, sponsored by William Stoops.
NCT06989853 is a Early Phase 1 study of Methamphetamine Use Disorder that is actively recruiting participants, run by William Stoops. The registered enrollment target is 40 participants, below the 52-participant average among 12 other Methamphetamine Use Disorder trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06989853, a Early Phase 1 study of Methamphetamine Use Disorder, is actively recruiting participants, sponsored by William Stoops.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a human laboratory study evaluating the influence of troriluzole treatment on the effects of methamphetamine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.
Primary Outcome
Number of Times Subjects Hypothetically Choose Methamphetamine Over Money between $0 and $140
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Methamphetamine
Study Locations (1)
Kentucky
- Psychopharmacology of Addiction Laboratory - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2029-02-28 |
| Phase | Early Phase 1 |
What NCT06989853 shows while recruiting
NCT06989853 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 52-participant average among 12 other Methamphetamine Use Disorder trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Methamphetamine Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06989853 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT06989853 about?
NCT06989853 is a clinical study titled "Methamphetamine and Troriluzole". This will be a human laboratory study evaluating the influence of troriluzole treatment on the effects of methamphetamine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.
What is the current status of trial NCT06989853?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2025-08-25. Estimated completion is 2029-02-28.
What conditions does trial NCT06989853 study?
This clinical trial studies the following conditions: Methamphetamine Use Disorder.
What interventions are being tested in trial NCT06989853?
The interventions under investigation include: Placebo (DRUG), Methamphetamine (DRUG).
Who is sponsoring clinical trial NCT06989853?
This trial is sponsored by William Stoops, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06989853 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06989853's enrollment target sits among peer trials
40 5th of 12 higher than 8 of 12 other Methamphetamine Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Methamphetamine Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin for Methamphetamine Addiction
RECRUITING · Early Phase 1
-
Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV
RECRUITING · Phase 2
-
Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder
RECRUITING · NA
-
Deep TMS of Neural Circuits Associated With Stimulant Use Disorder
RECRUITING · NA
-
Non-Abstinence Outcomes in Methamphetamine Use Disorder
RECRUITING · NA
-
Methamphetamine Cue-reactivity
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI